Pfizer and Bayer in deal for pipeline diabetes, obesity treatments

Share this article:
Pfizer and Bayer have entered an agreement granting Pfizer worldwide rights to Bayer’s pipeline DGAT-1 inhibitor treatments for obesity and diabetes. Both companies agreed that Bayer would receive an upfront fee, milestone payments and royalties on sales of any compounds that successfully make it to market. Financial terms of the deal were not disclosed. The deal is expected to close in the second half of 2006. The lead compound in the class, BAY 74-4113, is a potential treatment for Type 2 diabetes and obesity currently in Phase I of clinical development.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.